Monopar Therapeutics (MNPR) Short term Debt (2020)
Monopar Therapeutics has reported Short term Debt over the past 1 years, most recently at $67772.0 for Q3 2020.
- Short term Debt reached $67772.0 in Q3 2020 per MNPR's latest filing, up from $47379.0 in the prior quarter.
- Across five years, Short term Debt topped out at $67772.0 in Q3 2020 and bottomed at $47379.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 67,772.00 |
| Jun 30, 2020 | 47,379.00 |